망막용 생물제제 시장 : 약제 클래스별, 적응증별, 유통 채널별, 세계 예측

The Retinal Biologics Market size will grow at 8.2% CAGR during 2024-2032, driven by the increasing prevalence of retinal disorders. According to Ocular Therapeutix, an estimated 401.6 million people worldwide are affected by various forms of retinal disease. Conditions such as age-related macular degeneration (AMD), diabetic retinopathy, and retinal vein occlusion are becoming more common, largely due to an aging global population and the rising incidence of diabetes and hypertension. Retinal biologics, with their advanced therapeutic capabilities offer targeted and efficient treatment options.

Innovations in biotechnology have enabled the creation of novel treatments that specifically target the underlying causes of retinal diseases. These new biologic therapies offer improved efficacy and safety profiles compared to traditional treatments, providing significant benefits for patients with conditions like diabetic retinopathy. Ongoing research and clinical trials continue to address unmet medical needs and expand the therapeutic landscape.

The retinal biologics industry is classified based on drug class, indication, distribution channel, and region.

The TNF-a inhibitors segment will gain traction through 2032, as they work by blocking the tumor necrosis factor-alpha (TNF-a) protein. These inhibitors have shown significant efficacy in reducing inflammation and halting the progression of diseases such as diabetic retinopathy and uveitis. The effectiveness of TNF-a inhibitors in preserving vision and preventing further retinal damage makes them a valuable addition to the therapeutic arsenal for retinal disorders.

The online pharmacies segment will grow rapidly through 2032, owing to the easy access to a wide range of biologic treatments, including those for retinal disorders, often at competitive prices. The convenience of home delivery, coupled with the ability to consult healthcare professionals online, is making online pharmacies an attractive option for patients. The COVID-19 pandemic has accelerated the shift towards online purchasing, with many patients opting for digital channels to avoid in-person visits to pharmacies. This trend is expected to continue as more consumers become comfortable with online shopping for their healthcare needs.

Europe retinal biologics market size will expand at a steady pace through 2032, driven by a well-established healthcare infrastructure and high medical spending. The region's aging population is contributing to an increasing prevalence of retinal disorders, creating a substantial demand for effective treatments. Countries such as Germany, the United Kingdom, France, and Italy are at the forefront of adopting advanced retinal biologics, supported by strong regulatory frameworks and government initiatives aimed at improving eye health. Additionally, Europe is home to several leading pharmaceutical companies and research institutions that are actively involved in the development and commercialization of retinal biologics.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market scope & definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates & calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360 degree synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increasing prevalence of retinal diseases
    • 3.2.1.2 Rising research & development activities related to retinal biologics
    • 3.2.1.3 Advancements in biologic therapies
  • 3.2.2 Industry pitfalls & challenges
    • 3.2.2.1 Stringent regulatory requirements
    • 3.2.2.2 Risk of potential adverse effects
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Pipeline analysis
• 3.6 Porter's analysis
• 3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company matrix analysis
• 4.3 Competitive analysis of major market players
• 4.4 Competitive positioning matrix
• 4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Drug Class, 2021 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 VEGF-A antagonist
• 5.3 TNF-a inhibitor

Chapter 6 Market Estimates and Forecast, By Indication, 2021 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 Macular degeneration
• 6.3 Diabetic retinopathy
• 6.4 Uveitis
• 6.5 Other indications

Chapter 7 Market Estimates and Forecast, By Distribution Channel, 2021 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 Hospital pharmacies
• 7.3 Retail pharmacies
• 7.4 Online pharmacies

Chapter 8 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

• 8.1 Key trends
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 UK
  • 8.3.3 France
  • 8.3.4 Spain
  • 8.3.5 Italy
  • 8.3.6 Netherlands
  • 8.3.7 Rest of Europe
• 8.4 Asia Pacific
  • 8.4.1 China
  • 8.4.2 Japan
  • 8.4.3 India
  • 8.4.4 Australia
  • 8.4.5 South Korea
  • 8.4.6 Rest of Asia Pacific
• 8.5 Latin America
  • 8.5.1 Brazil
  • 8.5.2 Mexico
  • 8.5.3 Rest of Latin America
• 8.6 Middle East and Africa
  • 8.6.1 South Africa
  • 8.6.2 Saudi Arabia
  • 8.6.3 UAE
  • 8.6.4 Rest of Middle East and Africa

Chapter 9 Company Profiles

• 9.1 AbbVie Inc.
• 9.2 Amgen Inc.
• 9.3 Janssen Pharmaceuticals (Johnson & Johnson)
• 9.4 F-Hoffman La Roche Ltd.
• 9.5 Oxurion NV
• 9.6 Novartis AG
• 9.7 MeiraGTx Limited
• 9.8 Regeneron Pharmaceuticals Inc.
• 9.9 OncoGene Pharmaceuticals
• 9.10 SemaThera Inc.